title: Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria.
abstract: OBJECTIVE
  The study predicts long-term cervical cancer related population health and economic effects of introducing the HPV-vaccination for 12-year-old girls (and boys) in addition to current screening compared with screening only.
  
  
  METHODS
  Health effects are predicted by a dynamic transmission model. Model results are used to calculate incremental cost-effectiveness ratios (ICER) in euro per life year gained (LYG) for a time-horizon between 2008 and 2060 from a public payer and a societal perspective.
  
  
  RESULTS
  Vaccination of girls results a discounted ICER of euro 64,000/LYG and euro 50,000/LYG from a payer's and societal perspectives respectively. The additional vaccination of boys increases the ICER to euro 311,000 and euro 299,000/LYG respectively. Results were most sensitive to vaccination price, discount rate and time-horizon.
  
  
  CONCLUSIONS
  HPV-vaccination for girls should be cost-effective when adopting a longer time-horizon and a societal perspective. Applying a shorter time frame and a payer's perspective or vaccinating boys may not be cost-effective without reducing the vaccine price.
authors: Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, Austria. Ingrid.zechmeister@hta.lbg.ac.at
authors: Ingrid
authors: I
authors: Zechmeister
authors: Birgitte Freiesleben de
authors: BF
authors: Blasio
authors: Geoff
authors: G
authors: Garnett
authors: Aileen Rae
authors: AR
authors: Neilson
authors: Uwe
authors: U
authors: Siebert
mesh_terms: D001317:Austria; D002648:Child; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D008297:Male; D008403:Mass Screening / Q000191:economics; D018803:Models, Economic; D030361:Papillomavirus Infections / Q000191:economics / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics*; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000517:prevention & control* / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines